Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Lumoxiti (Moxetumomab pasudotox –tdfk) for the Treatment of Hairy Cell Leukaemia

Lumoxiti (Moxetumomab pasudotox) is developed by Medimmune, the biologics arm of AstraZeneca. Image courtesy of Medimune.



  • Moxetumomab pasudotox
  • Moxetumomab pasudotox
  • Moxetumomab pasudotox

Go Top